Extension of Time to File SOU

KOMPENIUM

Eli Lilly and Company

Trademark/Service Extension of Time

PTO Form 1581 (Rev 9/2005)
OMB No. 0651-0054 (Exp. 10/31/2017)

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 85372434
LAW OFFICE ASSIGNED LAW OFFICE 104
MARK SECTION
MARK KOMPENIUM
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT KOMPENIUM
OWNER SECTION
NAME Eli Lilly and Company
STREET Lilly Corporate Center
CITY Indianapolis
STATE Indiana
ZIP/POSTAL CODE 46285
COUNTRY United States
PHONE 317-276-9624
FAX 317-276-1919
EMAIL XXXX
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants
GOODS OR SERVICES DELETED FROM THE APPLICATION obesity
GOODS OR SERVICES FOR WHICH APPLICANT HAS A CONTINUED BONA FIDE INTENTION, AND IS ENTITLED, TO USE Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants
INTERNATIONAL CLASS 010
CURRENT IDENTIFICATION medical delivery device in the form of a syringe, injector device, and pen for injecting a pharmaceutical preparation; medical delivery device in the form of an inhaler for inhalation of a pharmaceutical preparation
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 3
ONGOING EFFORT product or service research or development
ALLOWANCE MAIL DATE 01/03/2012
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 2
SUBTOTAL AMOUNT 300
TOTAL AMOUNT 300
SIGNATURE SECTION
SIGNATURE /reljr44/
SIGNATORY'S NAME Robert E. Lee, Jr.
SIGNATORY'S POSITION Assistant General Patent Counsel
DATE SIGNED 05/28/2013
SIGNATORY'S PHONE NUMBER 317 276 9624
FILING INFORMATION
SUBMIT DATE Tue May 28 14:34:28 EDT 2013
TEAS STAMP USPTO/ESU-XX.XXX.XX.XX-20
130528143428443996-853724
34-500dba41bf8c115bd4e0ab
55ea173f819397c95ce26e5b4
e9018ade767e6cc04a-DA-755
-20130528101420665511



PTO Form 1581 (Rev 9/2005)
OMB No. 0651-0054 (Exp. 10/31/2017)


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: KOMPENIUM
SERIAL NUMBER: 85372434

The applicant, Eli Lilly and Company, having an address of
      Lilly Corporate Center
      Indianapolis, Indiana 46285
      United States
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 01/03/2012.

For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants

This filing does NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these goods/services are permanently deleted from this application: obesity

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class: Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants

For International Class 010:
Current identification: medical delivery device in the form of a syringe, injector device, and pen for injecting a pharmaceutical preparation; medical delivery device in the form of an inhaler for inhalation of a pharmaceutical preparation

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the third extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development



A fee payment in the amount of $300 will be submitted with the form, representing payment for 2 classes.


Declaration

The undersigned, being hereby warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. Section 1001, and that such willful false statements may jeopardize the validity of the form or any resulting registration, declares that he/she is properly authorized to execute this form on behalf of the applicant; he/she believes the applicant to be the owner of the trademark/service mark sought to be registered; and that all statements made of his/her own knowledge are true; and that all statements made on information and belief are believed to be true.


Signature: /reljr44/      Date Signed: 05/28/2013
Signatory's Name: Robert E. Lee, Jr.
Signatory's Position: Assistant General Patent Counsel
Signatory's Phone: 317 276 9624

RAM Sale Number: 85372434
RAM Accounting Date: 05/29/2013

Serial Number: 85372434
Internet Transmission Date: Tue May 28 14:34:28 EDT 2013
TEAS Stamp: USPTO/ESU-XX.XXX.XX.XX-20130528143428443
996-85372434-500dba41bf8c115bd4e0ab55ea1
73f819397c95ce26e5b4e9018ade767e6cc04a-D
A-755-20130528101420665511



Extension of Time to File SOU [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed